California Public Employees Retirement System boosted its position in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 39.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 72,557 shares of the specialty pharmaceutical company’s stock after buying an additional 20,496 shares during the quarter. California Public Employees Retirement System owned approximately 0.14% of Supernus Pharmaceuticals worth $4,343,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of SUPN. Principal Financial Group Inc. grew its stake in Supernus Pharmaceuticals by 3.2% in the 1st quarter. Principal Financial Group Inc. now owns 423,062 shares of the specialty pharmaceutical company’s stock valued at $19,376,000 after buying an additional 13,238 shares during the last quarter. Barclays PLC grew its stake in Supernus Pharmaceuticals by 115.7% in the 1st quarter. Barclays PLC now owns 24,319 shares of the specialty pharmaceutical company’s stock valued at $1,113,000 after buying an additional 13,047 shares during the last quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp acquired a new position in Supernus Pharmaceuticals in the 1st quarter valued at $852,000. Legal & General Group Plc grew its stake in Supernus Pharmaceuticals by 3.1% in the 1st quarter. Legal & General Group Plc now owns 104,580 shares of the specialty pharmaceutical company’s stock valued at $4,791,000 after buying an additional 3,120 shares during the last quarter. Finally, Xact Kapitalforvaltning AB acquired a new position in Supernus Pharmaceuticals in the 1st quarter valued at $399,000. Institutional investors and hedge funds own 97.45% of the company’s stock.
A number of analysts have weighed in on SUPN shares. Jefferies Financial Group increased their price target on shares of Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, August 9th. Cantor Fitzgerald set a $56.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 8th. BidaskClub downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, July 6th. Mizuho started coverage on shares of Supernus Pharmaceuticals in a report on Monday, September 17th. They issued a “buy” rating and a $61.00 price target for the company. Finally, ValuEngine raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, September 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $54.67.
Shares of Supernus Pharmaceuticals stock opened at $47.91 on Friday. The company has a quick ratio of 2.54, a current ratio of 2.74 and a debt-to-equity ratio of 0.82. Supernus Pharmaceuticals Inc has a fifty-two week low of $33.30 and a fifty-two week high of $61.25. The firm has a market capitalization of $2.63 billion, a price-to-earnings ratio of 38.02 and a beta of 0.79.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.14. Supernus Pharmaceuticals had a net margin of 24.17% and a return on equity of 30.57%. The firm had revenue of $99.54 million during the quarter, compared to the consensus estimate of $101.01 million. On average, equities research analysts expect that Supernus Pharmaceuticals Inc will post 1.97 earnings per share for the current fiscal year.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Featured Article: Market Capitalization in the Stock Market
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.